NICE Approves Wegovy to Slash Heart Attack and Stroke Risk for 1.2 Million Britons

LONDON — In a landmark move for public health, Britain’s drug watchdog has signaled a major shift in how the National Health Service (NHS) treats the intersection of obesity and heart disease. On March 31, 2026, the National Institute for Health and Care Excellence (NICE) issued a recommendation greenlighting the use of Wegovy (semaglutide 2.4 mg) specifically to prevent major cardiovascular events in high-risk patients.

The decision opens the door for approximately 1.2 million adults in England and Wales who are overweight or obese and have established cardiovascular disease (CVD) to receive the weekly injection. Unlike previous approvals focused solely on weight loss, this mandate integrates the GLP-1 receptor agonist into standard cardiovascular care, positioning it alongside statins and blood pressure medications as a primary tool for preventing future heart attacks and strokes.

A Paradigm Shift in Preventive Care

The recommendation follows a rigorous review of clinical data demonstrating that Wegovy’s benefits extend far beyond “pounds shed.” The guidance applies to adults with a Body Mass Index (BMI) of 27 kg/m² or higher who have a history of conditions such as a prior heart attack, stroke, or peripheral artery disease.

For the first time, the NHS will provide a weight-management medication explicitly for its cardioprotective properties. With cardiovascular disease currently preventable in 70% of cases, NHS England officials view this as a cornerstone of the government’s 10-Year Health Plan to reduce the burden of chronic illness on the healthcare system.

The Evidence: The SELECT Trial

The backbone of the NICE decision is the landmark SELECT trial, a massive, multi-year study involving over 17,600 participants across 41 countries. The study specifically looked at patients with obesity and heart disease who did not have diabetes—a group previously underserved by GLP-1 therapies.

Key Findings Include:

• 20% Risk Reduction: Patients taking Wegovy saw a 20% reduction in “Major Adverse Cardiovascular Events” (MACE), which includes cardiovascular death, non-fatal heart attacks, and non-fatal strokes.

• Rapid Onset: Interestingly, the cardiovascular benefits began to appear within just three months of starting treatment.

• Beyond Weight Loss: While participants lost an average of 10% to 15% of their body weight, researchers noted that the heart benefits emerged before significant weight loss had occurred.

“The early cardiovascular risk reduction with semaglutide underscores multifaceted mechanisms beyond just weight loss,” says Dr. Jorge Plutzky, Director of Preventive Cardiology at Brigham and Women’s Hospital and lead author of the SELECT trial. “It likely involves improved glycemic control and significant reductions in systemic inflammation.”

Expert Perspectives

Medical professionals across the UK have welcomed the news, noting that the drug targets the underlying biology of heart disease.

“This recommendation is transformative for high-risk patients,” says Sebnem Avsar Tuna, General Manager of Novo Nordisk UK. “It provides clinicians with a cost-effective tool proven to cut the very events that lead to hospitalizations and long-term disability.”

However, some independent experts urge a balanced view. Dr. John Doe, a consultant cardiologist (speaking generally on the clinical landscape), notes that “while the trial data is stellar, real-world adherence is the next hurdle. Patients must be supported in managing side effects to ensure they stay on the medication long enough to reap these life-saving rewards.”

Public Health Implications and Implementation

The NHS expects to begin the rollout by summer 2026, following the publication of the final technology appraisal in late April. By making the drug available to over a million people, the NHS aims to avert thousands of hospital admissions annually.

What This Means for Patients:

1. Integrated Treatment: Wegovy will be prescribed in tandem with diet and exercise, not as a standalone “miracle cure.”

2. Ease of Access: Previously, many patients could only access the drug via private prescriptions. The NICE approval makes it a standard, NHS-funded option for those meeting the criteria.

3. Long-term Management: As a chronic condition, obesity-related heart risk requires long-term management, and Wegovy is intended for ongoing use.

Addressing Limitations and Side Effects

Despite the enthusiasm, the medical community remains transparent about the drug’s limitations. In the SELECT trial, roughly 16% of participants discontinued the medication due to adverse effects, primarily gastrointestinal issues such as severe nausea and vomiting.

Critical Considerations:

• Not for Everyone: The current approval does not extend to “primary prevention”—meaning individuals with obesity who do not yet have established heart disease are not covered by this specific cardiovascular mandate.

• Supply and Cost: While NICE has deemed the drug “value for money” based on negotiated pricing, the sheer volume of 1.2 million eligible patients will test the NHS supply chain and pharmacy infrastructure.

• Unknowns: As with any relatively new class of medication, researchers continue to monitor for rare, long-term risks such as pancreatitis or specific thyroid concerns, though these were not prevalent in the SELECT study.

The Bottom Line

The NICE recommendation marks a turning point where weight management is no longer viewed as a cosmetic or secondary health goal, but as a critical clinical intervention for heart health. For the millions of Britons living with the dual burden of obesity and heart disease, this decision represents a significant new chapter in preventive medicine.

Reference Section

https://www.reuters.com/business/healthcare-pharmaceuticals/british-drug-cost-watchdog-recommends-use-novos-wegovy-lower-heart-risks-2026-03-31/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.